Recently, an abstract announced the phase III NATALEE study exploring three years of ribociclib demonstrated statistically significant improvement in invasive disease-free survival in patients with stage II and III HR+/HER2– breast cancer, including those with no nodal involvement27. Here, ERBB2 is linked to breast cancer.